SAN FRANCISCO, Jan. 22, 2014 /PRNewswire/ -- Nektar Therapeutics
(Nasdaq: NKTR) ("Nektar") today announced the pricing of its
previously announced underwritten public offering of 8,500,000
shares of its common stock at a public offering price of
$12.75 per share. In connection
with this offering, Nektar has also granted to the underwriters a
30-day option to purchase up to an additional 1,275,000 shares of
common stock.
J.P. Morgan and Jefferies are acting as joint book-running
managers in the offering. William
Blair, Cowen and Company, Piper
Jaffray, Brean Capital and Roth Capital Partners are acting
as co-managers for the offering.
Nektar intends to use the net proceeds from this offering for
general corporate purposes including research and development
funding and working capital.
The securities described above are being offered by Nektar
pursuant to an effective shelf registration statement, including a
prospectus supplement and accompanying prospectus, copies of which
may be obtained from the offices of J.P. Morgan Securities LLC,
attention Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York, NY 11717, or
telephone: 866-803-9204 or Jefferies LLC, Equity Syndicate
Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, or telephone: 877-547-6340 or by
emailing Prospectus_Department@Jefferies.com.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy these securities, nor will there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
SOURCE Nektar Therapeutics